<DOC>
	<DOCNO>NCT02554526</DOCNO>
	<brief_summary>Using whole blood sample plasma sample obtain hemophilia A patient inhibitor , investigator perform coagulation assessment co-presence aPCC factor VIII comprehensive coagulation assay flow chamber analysis blood flow condition .</brief_summary>
	<brief_title>Basic Study Combination Therapy Based APCC-induced FVllI Activation Hemophilia A Patients With Inhibitors</brief_title>
	<detailed_description>Comprehensive coagulation assay use recently popular rotational thromboelastometry ( ROTEM ) , factor Xa/thrombin/plasmin generation test , coagulation wave analysis recently develop flow chamber system blood flow condition ( T-TAS® ) use . A bypassing agent , aPCC ( Feiba® ) recombinant factor VIII ( Advate® ) add ex vivo whole blood plasma sample patient hemophilia A inhibitor compare coagulation effect aPCC presence factor VIII aPCC absence condition close physiological condition . Furthermore , difference coagulation effect difference inhibitor epitope examine .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients hemophilia A inhibitor ( Inhibitor titer ; &gt; 0.5 Bethesda U/ml ) Patients agreement consent patient signatures Patients fill condition describe</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>hemophilia A</keyword>
	<keyword>inhibitor</keyword>
	<keyword>bypass therapy</keyword>
	<keyword>factor VIII</keyword>
</DOC>